NCT06355050 Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer
| NCT ID | NCT06355050 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jena University Hospital |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2026-04-01 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital patient questionnaire is used to asses quality of life longitudinally. Quality of life (QoL) and toxicity profiles will be correlated with planning parameters and compared to retrospective cohorts of patients who underwent normofractionated RT or moderately hypofractionated RT, respectively.
Eligibility Criteria
Inclusion Criteria: * no androgen deprivation therapy within the last 2 months prior to RT * good performance status (Eastern Cooperative Oncology Group, ECOG, 0/1) * no secondary malignancy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06355050 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 120 Years, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06355050 currently recruiting?
Yes, NCT06355050 is actively recruiting participants. Contact the research team at strahlentherapie@med.uni-jena.de for enrollment information.
Where is the NCT06355050 trial being conducted?
This trial is being conducted at Jena, Germany.
Who is sponsoring the NCT06355050 clinical trial?
NCT06355050 is sponsored by Jena University Hospital. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.